AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03748745
Drug: SH229
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet, oral, 600 mg once daily for day 1 to day 14
Trial: NCT03748745
Drug: SH229
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet, oral, 600 mg once daily for day 8 to day 14
Trial: NCT03748745
Drug: Daclatasvir dihydrochloride
RxNorm normalized name: Daclatasvir dihydrochloride
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablet, oral, 60 mg once daily for day 8 to day 14
Trial: NCT03748745
Drug: Daclatasvir dihydrochloride
RxNorm normalized name: Daclatasvir dihydrochloride
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablet, oral, 60 mg once daily for day 1 to day 14
Trial: NCT01538875
Drug: Hydralazine
RxNorm normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
Trial: NCT01538875
Drug: Labetalol
RxNorm normalized name: Labetalol
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
Trial: NCT04375631
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04375631
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV then PO
Trial: NCT04375631
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04375631
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04375631
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT00229008
Drug: ceftobiprole plus placebo
DrugBank: Ceftobiprole (DB04918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
Trial: NCT00229008
Drug: linezolid plus ceftazidime
RxNorm normalized name: Linezolid
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
Trial: NCT00426023
Drug: Cyclosporine A 0,05% eye drop
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
Trial: NCT00426023
Drug: ketotifen fumarate 0.025% eye drops
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
Trial: NCT01557946
Drug: citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: citalopram 20-40 mg daily
Trial: NCT00393445
Drug: GLP-1 control
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion of GLP-1
Trial: NCT00393445
Drug: GLP-1 and Exendin(9-39) 300
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Trial: NCT00393445
Drug: saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of saline
Trial: NCT00393445
Drug: GLP-1 and Exendin(9-39) 600
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Trial: NCT00393445
Drug: GLP-1 and Exendin(9-39) 900
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Trial: NCT04375631
Drug: Mycophenolate Sodium
RxNorm normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01103739
Drug: PF-04531083
RxNorm normalized name: Pf-04531083
DrugBank: Pf-04531083 (DB12468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
Trial: NCT01797718
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
Trial: NCT02983604
Drug: GS-5829
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet(s) administered orally once daily
Trial: NCT02983604
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
Trial: NCT02983604
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15.
Trial: NCT02906553
Drug: Glyceryl Trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00393445
Drug: GLP-1 and Exendin(9-39) 1200
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Trial: NCT03297879
Drug: Exenatide or metformin hydrochloride
RxNorm normalized name: Exenatide
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
Trial: NCT01717235
Drug: Ropinirole hydrochloride CR Tablets 2mg
RxNorm normalized name: Ropinirole Hydrochloride
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Trial: NCT02734173
Drug: ABT450r-ABT267-ABT333 +/- Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
Trial: NCT03244644
Drug: Open label RBX2660 (only for confirmed CDI recurrence)
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
Trial: NCT02047006
Drug: Rivaroxaban 10 mg
RxNorm normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours.
Trial: NCT00699192
Drug: Amlodipine 5 mg
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule amlodipine 5 mg orally once daily
Trial: NCT00699192
Drug: Valsartan 80 mg
RxNorm normalized name: valsartan 80 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 capsule valsartan 80 mg orally once daily
Trial: NCT00699192
Drug: Valsartan 40 mg
RxNorm normalized name: valsartan 40 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 capsule valsartan 40 mg orally once daily
Trial: NCT00004396
Drug: heme arginate
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004396
Drug: tin mesoporphyrin
RxNorm normalized name: Tin mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00289822
Drug: intracoronary infusion of progenitor cells
RxNorm normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01130506
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01130506
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01130506
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01053312
Drug: [18F] Flutemetamol
DrugBank: Flutemetamol (18F) (DB09151)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).
Trial: NCT00640367
Drug: Alteplase IV
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous recombinant tissue plasminogen activator
Trial: NCT04252495
Drug: Aprocitentan
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 25 mg.
Trial: NCT02502981
Drug: Chlortalidone
RxNorm normalized name: Chlortalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg orally once a day for 40 weeks
Trial: NCT01555671
Drug: Meperidine
RxNorm normalized name: Meperidine
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml meperidine injection intravenously injected in randomly selected patients
Trial: NCT01555671
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 ml saline solution injection intravenously injected in randomly selected patients
Trial: NCT01709227
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
Trial: NCT00426478
Drug: Amlodipine (5mg)
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02352493
Drug: ALN-CC5
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
Trial: NCT02352493
Drug: Sterile Normal Saline (0.9% NaCl)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calculated volume to match active comparator
Trial: NCT04375631
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04375631
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03777514
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: treatment of iron deficiency anemia with IV iron.
Trial: NCT03777514
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment of iron deficiency anemia with oral iron
Trial: NCT02889549
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
Trial: NCT02889549
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
Trial: NCT00477711
Drug: cetuximab, cisplatin, capecitabine
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
Trial: NCT02890719
Drug: Grazoprevir 100 mg/day
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Grazoprevir 100 mg/ day 12 weeks
Trial: NCT02890719
Drug: Elbasvir 50 mg/d
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elbasvir 50 mg/day 12 weeks
Trial: NCT02890719
Drug: Grazoprevir 100 mg/day
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Grazoprevir 100 mg/day 16 weeks
Trial: NCT02890719
Drug: Elbasvir 50 mg/day
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elbasvir 50 mg/d 16 weeks
Trial: NCT02890719
Drug: Ribavirin 1200 mg/day
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin 1200 mg/day 16 weeks
Trial: NCT02207907
Drug: Sodium bicarbonate plus sodium fluoride
RxNorm normalized name: sodium bicarbonate / sodium fluoride
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
Trial: NCT02207907
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toothpaste containing 1100 ppm fluoride as sodium fluoride
Trial: NCT00215930
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
Trial: NCT00215930
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
Trial: NCT00215930
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.
Trial: NCT00215930
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.
Trial: NCT00158184
Drug: oxycodone 15 mg
RxNorm normalized name: oxyCODONE 15 mg oral tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/70 kg oxycodone administered once per day, orally.
Trial: NCT00158184
Drug: oxycodone 30 mg
RxNorm normalized name: oxycodone 30 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg/70 kg oxycodone administered once per day, orally.
Trial: NCT00873002
Drug: panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
Trial: NCT00873002
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg PO BID
Trial: NCT03467178
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nucleic Acid Synthesis Inhibitor
Trial: NCT03467178
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy medication
Trial: NCT03467178
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy medication
Trial: NCT03467178
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy medication
Trial: NCT01831089
Drug: PM01183 + paclitaxel +/- bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients
Trial: NCT01994486
Drug: Telaprevir and Sofosbuvir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
Trial: NCT00085410
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03254173
Drug: Mirtazapine 30 mg oral tablets
RxNorm normalized name: mirtazapine 30 MG
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks